出版：MarketsandMarkets（マーケッツアンドマーケッツ） 出版年月：2022年11月
血液腫瘍検査市場 : 製品とサービス (サービス、アッセイキット)、がん (白血病 (急性骨髄性、急性リンパ性)、リンパ腫 (非ホジキン、ホジキン)、テクノロジー (PCR、NGS)、エンド ユーザー – 2027 年までの世界予測
Hemato Oncology Testing Market by Product & Services (Services, Assay Kits), Cancer (Leukemia (Acute Myeloid, Acute Lymphocytic), Lymphoma (Non-Hodgkin, Hodgkin), Technology (PCR, NGS), End User – Global Forecast to 2027
| ページ数 | 141 |
| 図表数 | 129 |
| 種別 | 英文調査報告書 |
| 価格 |
The global Hemato oncology testing market is projected to reach USD 5.6 billion by 2027 from an estimated USD 2.9 Billion in 2022, at a CAGR of 14.2%. The growth in this market is attributed to the growing incidence of hematologic cancer, increasing collaborations, and the increasing number of conferences on personalized medicine.
“The Services segment accounted for the highest growth rate in the Hemato oncology testing market, by product and services type, during the forecast period”
On the basis of products & services type, the global hemato oncology testing market is segmented into services and assay kits.
In 2021, The services segment accounted for the largest share of the global hemato oncology testing market in 2021. This can be attributed to the increase in the number of hematologic cancer significantly. Hence the the patient needs continuous monitoring and testing during the treatment, the increasing collaration between the companies for conducting the clinical trails on the hematologic cancers requires the hemato oncology testing products and the raising number of the diagonostic centers for diagonotic testing procudures is expected to boost the demand for the the services segment in the hemato oncology testing product market .
“Lymphoma segment accounted for the highest CAGR by cancer type, during the forecast period”
By cancer type, the global leukemia, lymphoma, and other cancers market. In 2021, the lymphoma segment dominated the global market. This can be attributed to factor such as the increasing prevalence lymphoma and the risisng geriatric population across sthe globe is supporting the increasing incidence of the lymphoma cases which is a major driving factor for this market.
“The PCR segment accounted for the highest growth rate in the Hemato oncology testing market, by technology type, during the forecast period”
Based on type, the Hemato oncology testing market technology is segmented into PCR, IHC, NGS, cytogenetics, and other technologies.
In 2021, the PCR segment dominated hemato oncology testing market. Factors supporting the growth of the segment is the wide use of this technology owing to its ease of use and easy availability of assay kits.
“The Asia-Pacific market is expected to grow at the highest CAGR during the forecast period.”
The Hemato oncology testing market is segmented into – North America, Europe, the Asia Pacific and ROW. The Hemato oncology testing market in several Asia-Pacific countries is expected to witness high growth during the forecast period. Market growth will be driven by the rising geriatric population, increasing demand for quality healthcare, and the growing focus on cancer biomarkers by various stakeholders in their respective healthcare systems.
A breakdown of the primary participants referred to for this report is provided below:
• By Company Type: Tier 1–45%, Tier 2–35%, and Tier 3– 45%
• By Designation: C-level–32%, Director-level–20%, and Others–48%
• By Region: North America–35%, Europe–28%, Asia Pacific–25%, ROW¬—12%
Lists of Companies Profiled in the Report:
• Abbott Laboratories (US)
• F. Hoffman-La Roche (Switzerland)
• QIAGEN (Germany)
• Thermo Fisher Scientific (US)
• Illumina (US)
• Bio-Rad Laboratories (US)q
• MolecularMD (Ireland)
• ArcherDX (US)
• ARUP Laboratories (US)
• Asuragen (US)
• Invivoscribe (US)
• Adaptive Biotechnologies (US)
• Amoy Diagnostics (China)
• ELITechGroup (France)
• Vela Diagnostics (Singapore)
• Gentronix (UK)
• BioIVT (US)
• SAGA Diagnostics (Sweden)
• Olink (Sweden)
• Cancer Diagnostics (US)
Research Coverage
This report studies the Hemato oncology testing market based on the type of product, cancer, technology and region. The report also studies factors (such as drivers, restraints, opportunities, and challenges) affecting market growth. It analyzes the opportunities and challenges in the market and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micromarkets with respect to their individual growth trends and forecasts the revenue of the market segments with respect to five main regions (and the respective countries in these regions.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall Hemato oncology testing market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide them with information on the key market drivers, restraints, opportunities and challenges.
目次
1 INTRODUCTION 20
1.1 STUDY OBJECTIVES 20
1.2 MARKET DEFINITION 20
1.2.1 INCLUSIONS & EXCLUSIONS 21
1.3 STUDY SCOPE 21
FIGURE 1 MARKETS COVERED 21
1.3.1 REGIONAL SCOPE 22
1.3.2 YEARS CONSIDERED 22
1.4 CURRENCY CONSIDERED 22
1.5 LIMITATIONS 23
1.6 MARKET STAKEHOLDERS 23
1.7 SUMMARY OF CHANGES 23
2 RESEARCH METHODOLOGY 25
2.1 RESEARCH DATA 25
FIGURE 2 RESEARCH DESIGN 25
2.2 SECONDARY DATA 26
2.2.1 SECONDARY SOURCES 26
2.2.2 KEY DATA FROM SECONDARY SOURCES 26
2.3 PRIMARY DATA 27
FIGURE 3 PRIMARY SOURCES 27
2.3.1 KEY DATA FROM PRIMARY SOURCES 28
2.3.2 KEY INDUSTRY INSIGHTS 29
2.4 BREAKDOWN OF PRIMARY INTERVIEWS 29
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY- AND DEMAND-SIDE PARTICIPANTS 29
FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 30
2.5 MARKET SIZE ESTIMATION 30
FIGURE 6 HEMATO-ONCOLOGY TESTING MARKET: BOTTOM-UP APPROACH 31
2.5.1 GROWTH FORECAST 32
FIGURE 7 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 32
2.5.2 TOP-DOWN APPROACH 33
FIGURE 8 HEMATO-ONCOLOGY TESTING MARKET: TOP-DOWN APPROACH 33
2.6 MARKET BREAKDOWN AND DATA TRIANGULATION 34
FIGURE 9 DATA TRIANGULATION METHODOLOGY 34
2.7 RESEARCH ASSUMPTIONS 35
2.8 STUDY ASSUMPTIONS 35
2.9 INDICATORS AND OTHER ASSUMPTIONS 36
2.10 RISK ASSESSMENT 36
TABLE 1 RISK ASSESSMENT 36
2.11 RESEARCH LIMITATIONS 36
3 EXECUTIVE SUMMARY 37
FIGURE 10 HEMATO-ONCOLOGY TESTING MARKET, BY PRODUCT & SERVICE, 2022 VS. 2027 (USD MILLION) 37
FIGURE 11 HEMATO-ONCOLOGY TESTING MARKET, BY CANCER TYPE, 2022 VS. 2027 (USD MILLION) 38
FIGURE 12 HEMATO-ONCOLOGY TESTING MARKET, BY TECHNOLOGY, 2022 VS. 2027 (USD MILLION) 38
FIGURE 13 HEMATO-ONCOLOGY TESTING MARKET, BY END USER, 2022 VS. 2027 (USD MILLION) 39
FIGURE 14 HEMATO-ONCOLOGY TESTING MARKET, BY REGION, 2022 VS. 2027 (USD MILLION) 39
4 PREMIUM INSIGHTS 41
4.1 HEMATO-ONCOLOGY TESTING MARKET OVERVIEW 41
FIGURE 15 GROWING INCIDENCE OF HEMATOLOGIC CANCERS TO DRIVE MARKET GROWTH 41
4.2 NORTH AMERICA: HEMATO-ONCOLOGY TESTING MARKET, BY PRODUCT & SERVICE (2021) 42
FIGURE 16 HEMATO-ONCOLOGY TESTING SERVICES DOMINATED NORTH AMERICAN MARKET IN 2021 42
4.3 GEOGRAPHICAL SNAPSHOT OF HEMATO-ONCOLOGY TESTING MARKET 42
FIGURE 17 NORTH AMERICA ACCOUNTED FOR LARGEST MARKET SHARE IN 2021 42
5 MARKET OVERVIEW 43
5.1 INTRODUCTION 43
5.2 MARKET DYNAMICS 43
FIGURE 18 HEMATO-ONCOLOGY TESTING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 43
5.2.1 DRIVERS 44
5.2.1.1 Growing incidence of hematologic cancer 44
TABLE 1 GLOBAL HEMATOLOGIC CANCER INCIDENCE, BY TYPE, 2020–2040 44
TABLE 2 GLOBAL GERIATRIC POPULATION, BY REGION, 2019 VS. 2030 44
5.2.1.2 Increasing collaborations between companies 45
5.2.1.3 Rising number of private diagnostic centers 45
5.2.1.4 Increasing conferences on personalized medicine 46
TABLE 3 HEMATO-ONCOLOGY TESTING MARKET: DETAILED LIST OF CONFERENCES AND EVENTS, 2022–2023 46
5.2.2 RESTRAINTS 47
5.2.2.1 Unfavorable reimbursement scenario 47
TABLE 4 REIMBURSEMENT SCENARIO FOR HEMATO-ONCOLOGY TESTING PRODUCTS ACROSS REGIONS 47
5.2.2.2 Complex regulatory frameworks delaying approval of new molecular diagnostic tests 48
5.2.2.3 High capital investments and low cost-benefit ratio for biomarkers 48
5.2.3 OPPORTUNITIES 48
5.2.3.1 Emerging markets 48
TABLE 5 CAPITAL HEALTH EXPENDITURE, BY COUNTRY, 2019 49
TABLE 6 INCIDENCE OF HEMATOLOGIC CANCERS, BY COUNTRY, 2020 VS. 2040 49
5.2.3.2 Drug diagnostics co-development 49
5.2.4 CHALLENGES 50
5.2.4.1 Intellectual property rights protection issues 50
5.2.4.2 Shortage of trained professionals 50
6 HEMATO-ONCOLOGY TESTING MARKET, BY PRODUCT & SERVICE 51
6.1 INTRODUCTION 52
TABLE 7 HEMATO-ONCOLOGY TESTING MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION) 52
6.2 SERVICES 52
6.2.1 RISING INCIDENCE OF HEMATOLOGIC CANCERS TO INCREASE DEMAND FOR HEMATO-ONCOLOGY SERVICES 52
TABLE 8 HEMATO-ONCOLOGY TESTING SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION) 53
TABLE 9 HEMATO-ONCOLOGY TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 53
6.3 ASSAY KITS 53
6.3.1 GROWING FOCUS ON DEVELOPMENT OF ADVANCED ASSAY KITS TO DRIVE GROWTH 53
TABLE 10 HEMATO-ONCOLOGY TESTING ASSAY KITS MARKET, BY REGION, 2020–2027 (USD MILLION) 54
7 HEMATO-ONCOLOGY TESTING MARKET, BY CANCER TYPE 55
7.1 INTRODUCTION 56
TABLE 11 HEMATO-ONCOLOGY TESTING MARKET, BY CANCER TYPE, 2020–2027 (USD MILLION) 56
7.2 LEUKEMIA 56
FIGURE 19 GLOBAL LEUKEMIA INCIDENCE, 2020 57
TABLE 12 HEMATO-ONCOLOGY TESTING MARKET FOR LEUKEMIA, BY REGION, 2020–2027 (USD MILLION) 57
TABLE 13 HEMATO-ONCOLOGY TESTING MARKET FOR LEUKEMIA, BY TYPE, 2020–2027 (USD MILLION) 58
7.2.1 ACUTE MYELOID LEUKEMIA 58
7.2.1.1 High incidence of AML in adults to drive growth 58
TABLE 14 HEMATO-ONCOLOGY TESTING MARKET FOR ACUTE MYELOID LEUKEMIA, BY REGION, 2020–2027 (USD MILLION) 58
7.2.2 ACUTE LYMPHOCYTIC LEUKEMIA 58
7.2.2.1 High incidence of ALL in children to support growth 58
TABLE 15 HEMATO-ONCOLOGY TESTING MARKET FOR ACUTE LYMPHOCYTIC LEUKEMIA, BY REGION, 2020–2027 (USD MILLION) 59
7.2.3 OTHER LEUKEMIAS 59
TABLE 16 HEMATO-ONCOLOGY TESTING MARKET FOR OTHER LEUKEMIAS, BY REGION, 2020–2027 (USD MILLION) 59
7.3 LYMPHOMA 60
TABLE 17 HEMATO-ONCOLOGY TESTING MARKET FOR LYMPHOMA, BY REGION, 2020–2027 (USD MILLION) 60
TABLE 18 HEMATO-ONCOLOGY TESTING MARKET FOR LYMPHOMA, BY TYPE, 2020–2027 (USD MILLION) 60
7.3.1 NON-HODGKIN LYMPHOMA 61
7.3.1.1 Non-Hodgkin lymphoma to dominate market during forecast period 61
FIGURE 20 GLOBAL INCIDENCE OF NON-HODGKIN LYMPHOMA, 2020 61
TABLE 19 HEMATO-ONCOLOGY TESTING MARKET FOR NON-HODGKIN LYMPHOMA, BY REGION, 2020–2027 (USD MILLION) 61
7.3.2 HODGKIN LYMPHOMA 62
7.3.2.1 APAC hemato-oncology testing market for Hodgkin lymphoma to grow at highest rate 62
FIGURE 21 GLOBAL INCIDENCE OF HODGKIN LYMPHOMA, 2020 62
TABLE 20 HEMATO-ONCOLOGY TESTING MARKET FOR HODGKIN LYMPHOMA, BY REGION, 2020–2027 (USD MILLION) 62
7.4 OTHER CANCERS 63
TABLE 21 HEMATO-ONCOLOGY TESTING MARKET FOR OTHER CANCERS, BY REGION, 2020–2027 (USD MILLION) 63
8 HEMATO-ONCOLOGY TESTING MARKET, BY TECHNOLOGY 64
8.1 INTRODUCTION 65
TABLE 22 HEMATO-ONCOLOGY TESTING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 65
8.2 PCR 65
8.2.1 PCR TECHNOLOGY TO DOMINATE HEMATO-ONCOLOGY TESTING MARKET 65
TABLE 23 HEMATO-ONCOLOGY TESTING MARKET FOR PCR, BY REGION, 2020–2027 (USD MILLION) 66
8.3 IHC 66
8.3.1 ABILITY TO VISUALIZE TARGETED COMPONENTS IN SAMPLES TO BOOST ADOPTION 66
TABLE 24 HEMATO-ONCOLOGY TESTING MARKET FOR IHC, BY REGION, 2020–2027 (USD MILLION) 66
8.4 NGS 67
8.4.1 NGS SEGMENT TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD 67
TABLE 25 HEMATO-ONCOLOGY TESTING MARKET FOR NGS, BY REGION, 2020–2027 (USD MILLION) 67
8.5 CYTOGENETICS 67
8.5.1 HEAVY DEPENDENCE ON CYTOGENETIC ANALYSIS FOR DIAGNOSIS OF LEUKEMIA AND LYMPHOMA TO FUEL GROWTH 67
TABLE 26 HEMATO-ONCOLOGY TESTING MARKET FOR CYTOGENETICS, BY REGION, 2020–2027 (USD MILLION) 68
8.6 OTHER TECHNOLOGIES 68
TABLE 27 HEMATO-ONCOLOGY TESTING MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2020–2027 (USD MILLION) 69
9 HEMATO-ONCOLOGY TESTING MARKET, BY END USER 70
9.1 INTRODUCTION 71
TABLE 28 HEMATO-ONCOLOGY TESTING MARKET, BY END USER, 2020–2027 (USD MILLION) 71
9.2 CLINICAL LABORATORIES 71
9.2.1 PRESENCE OF ADVANCED INFRASTRUCTURE TO DRIVE MARKET 71
TABLE 29 HEMATO-ONCOLOGY TESTING MARKET FOR CLINICAL LABORATORIES, BY REGION, 2020–2027 (USD MILLION) 72
9.3 HOSPITALS 72
9.3.1 HIGH PATIENT FOOTFALL TO SUPPORT GROWTH 72
TABLE 30 HEMATO-ONCOLOGY TESTING MARKET FOR HOSPITALS, BY REGION, 2020–2027 (USD MILLION) 72
9.4 ACADEMIC & RESEARCH INSTITUTES 73
9.4.1 GROWING MEDICAL RESEARCH AND DRUG DEVELOPMENT IN ACADEMIC & RESEARCH INSTITUTES TO FUEL GROWTH 73
TABLE 31 HEMATO-ONCOLOGY TESTING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2020–2027 (USD MILLION) 73
9.5 OTHER END USERS 73
TABLE 32 HEMATO-ONCOLOGY TESTING MARKET FOR OTHER END USERS, BY REGION, 2020–2027 (USD MILLION) 74
10 HEMATO-ONCOLOGY TESTING MARKET, BY REGION 75
10.1 INTRODUCTION 76
TABLE 33 HEMATO-ONCOLOGY TESTING MARKET, BY REGION, 2020–2027 (USD MILLION) 76
10.2 NORTH AMERICA 76
FIGURE 22 NORTH AMERICA: HEMATO-ONCOLOGY TESTING MARKET SNAPSHOT 77
TABLE 34 NORTH AMERICA: HEMATO-ONCOLOGY TESTING MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 77
TABLE 35 NORTH AMERICA: HEMATO-ONCOLOGY TESTING MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION) 78
TABLE 36 NORTH AMERICA: HEMATO-ONCOLOGY TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 78
TABLE 37 NORTH AMERICA: HEMATO-ONCOLOGY TESTING MARKET, BY CANCER TYPE, 2020–2027 (USD MILLION) 78
TABLE 38 NORTH AMERICA: HEMATO-ONCOLOGY TESTING MARKET FOR LEUKEMIA, BY TYPE, 2020–2027 (USD MILLION) 79
TABLE 39 NORTH AMERICA: HEMATO-ONCOLOGY TESTING MARKET FOR LYMPHOMA, BY TYPE, 2020–2027 (USD MILLION) 79
TABLE 40 NORTH AMERICA: HEMATO-ONCOLOGY TESTING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 79
TABLE 41 NORTH AMERICA: HEMATO-ONCOLOGY TESTING MARKET, BY END USER, 2020–2027 (USD MILLION) 80
10.2.1 US 80
10.2.1.1 US to dominate North American hemato-oncology testing market during forecast period 80
TABLE 42 US: LEUKEMIA AT A GLANCE 80
TABLE 43 US: HEMATO-ONCOLOGY TESTING MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION) 81
TABLE 44 US: HEMATO-ONCOLOGY TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 81
TABLE 45 US: HEMATO-ONCOLOGY TESTING MARKET, BY CANCER TYPE, 2020–2027 (USD MILLION) 82
TABLE 46 US: HEMATO-ONCOLOGY TESTING MARKET FOR LEUKEMIA, BY TYPE, 2020–2027 (USD MILLION) 82
TABLE 47 US: HEMATO-ONCOLOGY TESTING MARKET FOR LYMPHOMA, BY TYPE, 2020–2027 (USD MILLION) 82
TABLE 48 US: HEMATO-ONCOLOGY TESTING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 83
TABLE 49 US: HEMATO-ONCOLOGY TESTING MARKET, BY END USER,
2020–2027 (USD MILLION) 83
10.2.2 CANADA 83
10.2.2.1 Initiatives undertaken by healthcare authorities to support growth of market 83
TABLE 50 CANADA: HEMATO-ONCOLOGY TESTING MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION) 84
TABLE 51 CANADA: HEMATO-ONCOLOGY TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 84
TABLE 52 CANADA: HEMATO-ONCOLOGY TESTING MARKET, BY CANCER TYPE, 2020–2027 (USD MILLION) 84
TABLE 53 CANADA: HEMATO-ONCOLOGY TESTING MARKET FOR LEUKEMIA, BY TYPE, 2020–2027 (USD MILLION) 85
TABLE 54 CANADA: HEMATO-ONCOLOGY TESTING MARKET FOR LYMPHOMA, BY TYPE, 2020–2027 (USD MILLION) 85
TABLE 55 CANADA: HEMATO-ONCOLOGY TESTING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 85
TABLE 56 CANADA: HEMATO-ONCOLOGY TESTING MARKET, BY END USER, 2020–2027 (USD MILLION) 86
10.3 EUROPE 86
10.3.1 RISING FOCUS ON BIOMARKER DEVELOPMENT IN EU COUNTRIES TO SUPPORT MARKET 86
TABLE 57 EUROPE: HEMATO-ONCOLOGY TESTING MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION) 86
TABLE 58 EUROPE: HEMATO-ONCOLOGY TESTING MARKET, BY CANCER TYPE, 2020–2027 (USD MILLION) 87
TABLE 59 EUROPE: HEMATO-ONCOLOGY TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 87
TABLE 60 EUROPE: HEMATO-ONCOLOGY TESTING MARKET FOR LEUKEMIA, BY TYPE, 2020–2027 (USD MILLION) 87
TABLE 61 EUROPE: HEMATO-ONCOLOGY TESTING MARKET FOR LYMPHOMA, BY TYPE, 2020–2027 (USD MILLION) 88
TABLE 62 EUROPE: HEMATO-ONCOLOGY TESTING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 88
TABLE 63 EUROPE: HEMATO-ONCOLOGY TESTING MARKET, BY END USER, 2020–2027 (USD MILLION) 88
10.4 ASIA PACIFIC 89
10.4.1 ASIA PACIFIC MARKET TO WITNESS HIGHEST GROWTH DURING FORECAST PERIOD 89
FIGURE 23 ASIA PACIFIC: HEMATO-ONCOLOGY TESTING MARKET SNAPSHOT 89
TABLE 64 ASIA PACIFIC: HEMATO-ONCOLOGY TESTING MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION) 90
TABLE 65 ASIA PACIFIC: HEMATO-ONCOLOGY TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 90
TABLE 66 ASIA PACIFIC: HEMATO-ONCOLOGY TESTING MARKET, BY CANCER TYPE, 2020–2027 (USD MILLION) 90
TABLE 67 ASIA PACIFIC: HEMATO-ONCOLOGY TESTING MARKET FOR LEUKEMIA, BY TYPE, 2020–2027 (USD MILLION) 91
TABLE 68 ASIA PACIFIC: HEMATO-ONCOLOGY TESTING MARKET FOR LYMPHOMA, BY TYPE, 2020–2027 (USD MILLION) 91
TABLE 69 ASIA PACIFIC: HEMATO-ONCOLOGY TESTING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 91
TABLE 70 ASIA PACIFIC: HEMATO-ONCOLOGY TESTING MARKET, BY END USER, 2020–2027 (USD MILLION) 92
10.5 REST OF THE WORLD 92
TABLE 71 REST OF THE WORLD: HEMATO-ONCOLOGY TESTING MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION) 92
TABLE 72 REST OF THE WORLD: HEMATO-ONCOLOGY TESTING SERVICES MARKET, BY TYPE, 2020–2027 (USD MILLION) 93
TABLE 73 REST OF THE WORLD: HEMATO-ONCOLOGY TESTING MARKET, BY CANCER TYPE, 2020–2027 (USD MILLION) 93
TABLE 74 REST OF THE WORLD: HEMATO-ONCOLOGY TESTING MARKET FOR LEUKEMIA, BY TYPE, 2020–2027 (USD MILLION) 93
TABLE 75 REST OF THE WORLD: HEMATO-ONCOLOGY TESTING MARKET FOR LYMPHOMA, BY TYPE, 2020–2027 (USD MILLION) 94
TABLE 76 REST OF THE WORLD: HEMATO-ONCOLOGY TESTING MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION) 94
TABLE 77 REST OF THE WORLD: HEMATO-ONCOLOGY TESTING MARKET, BY END USER, 2020–2027 (USD MILLION) 94
11 COMPETITIVE LANDSCAPE 95
11.1 OVERVIEW 95
11.2 STRATEGIES ADOPTED BY KEY PLAYERS/RIGHT TO WIN 95
TABLE 78 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN HEMATO-ONCOLOGY TESTING MARKET 95
11.3 MARKET SHARE ANALYSIS, 2021 96
TABLE 79 HEMATO-ONCOLOGY TESTING MARKET: DEGREE OF COMPETITION 96
11.4 COMPANY EVALUATION MATRIX 97
11.4.1 STARS 97
11.4.2 EMERGING LEADERS 97
11.4.3 PERVASIVE PLAYERS 98
11.4.4 PARTICIPANTS 98
FIGURE 24 HEMATO-ONCOLOGY TESTING MARKET: COMPETITIVE LEADERSHIP MAPPING (2021) 98
11.5 KEY STRATEGIES 99
11.5.1 PRODUCT LAUNCHES 99
TABLE 80 KEY PRODUCT LAUNCHES, JANUARY 2019–NOVEMBER 2022 99
11.5.2 DEALS 99
TABLE 81 KEY DEALS, JANUARY 2019–AUGUST 2022 99
11.5.3 OTHER DEVELOPMENTS 100
TABLE 82 OTHER KEY DEVELOPMENTS, JANUARY 2019–NOVEMBER 2022 100
12 COMPANY PROFILES 101
12.1 KEY PLAYERS 101
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
12.1.1 ABBOTT LABORATORIES 101
TABLE 83 ABBOTT LABORATORIES: BUSINESS OVERVIEW 101
FIGURE 25 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2021) 102
12.1.2 F. HOFFMANN-LA ROCHE AG 104
TABLE 84 F. HOFFMANN-LA ROCHE AG: BUSINESS OVERVIEW 104
FIGURE 26 F. HOFFMANN-LA ROCHE AG: COMPANY SNAPSHOT (2021) 104
12.1.3 QIAGEN N.V. 107
TABLE 85 QIAGEN N.V.: BUSINESS OVERVIEW 107
FIGURE 27 QIAGEN N.V.: COMPANY SNAPSHOT (2021) 108
12.1.4 THERMO FISHER SCIENTIFIC, INC. 111
TABLE 86 THERMO FISHER SCIENTIFIC, INC.: BUSINESS OVERVIEW 111
FIGURE 28 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT (2021) 112
12.1.5 ILLUMINA, INC. 115
TABLE 87 ILLUMINA, INC.: BUSINESS OVERVIEW 115
FIGURE 29 ILLUMINA, INC.: COMPANY SNAPSHOT (2021) 116
12.1.6 BIO-RAD LABORATORIES, INC. 119
TABLE 88 BIO-RAD LABORATORIES, INC.: BUSINESS OVERVIEW 119
FIGURE 30 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2021) 120
12.1.7 MOLECULARMD (A SUBSIDIARY OF ICON PLC) 122
TABLE 89 ICON PLC: BUSINESS OVERVIEW 122
FIGURE 31 ICON PLC: COMPANY SNAPSHOT (2021) 122
12.1.8 ADAPTIVE BIOTECHNOLOGIES 124
TABLE 90 ADAPTIVE BIOTECHNOLOGIES: BUSINESS OVERVIEW 124
FIGURE 32 ADAPTIVE BIOTECHNOLOGIES: COMPANY SNAPSHOT (2021) 124
12.1.9 ARCHERDX, INC. (A SUBSIDIARY OF INVITAE CORPORATION) 126
TABLE 91 ARCHERDX, INC.: BUSINESS OVERVIEW 126
12.1.10 ARUP LABORATORIES, INC. 128
TABLE 92 ARUP LABORATORIES, INC.: BUSINESS OVERVIEW 128
12.1.11 ASURAGEN, INC. 130
TABLE 93 ASURAGEN, INC.: BUSINESS OVERVIEW 130
12.1.12 INVIVOSCRIBE, INC. 131
TABLE 94 INVIVOSCRIBE, INC.: BUSINESS OVERVIEW 131
12.1.13 AMOY DIAGNOSTICS CO., LTD. 133
TABLE 95 AMOY DIAGNOSTICS CO., LTD.: BUSINESS OVERVIEW 133
12.1.14 ELITECHGROUP 134
TABLE 96 ELITECHGROUP: BUSINESS OVERVIEW 134
12.1.15 VELA DIAGNOSTICS 135
TABLE 97 VELA DIAGNOSTICS: BUSINESS OVERVIEW 135
12.2 OTHER PLAYERS 136
12.2.1 GENTRONIX LIMITED 136
12.2.2 BIOIVT 136
12.2.3 SAGA DIAGNOSTICS 137
12.2.4 OLINK 137
12.2.5 CANCER DIAGNOSTICS, INC. 137
*Details on Business Overview, Products Offered, Recent Developments, and MnM View
(Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
13 APPENDIX 138
13.1 DISCUSSION GUIDE 138
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 142
13.3 CUSTOMIZATION OPTIONS 144
13.4 RELATED REPORTS 144
13.5 AUTHOR DETAILS 145